Lantheus (NASDAQ:LNTH) Price Target Cut to $84.00 by Analysts at B. Riley

Lantheus (NASDAQ:LNTH) had its price objective reduced by B. Riley from $109.00 to $84.00 in a report issued on Tuesday morning,Benzinga reports. They currently have a buy rating on the medical equipment provider’s stock.

A number of other analysts have also recently commented on LNTH. JMP Securities dropped their price objective on Lantheus from $112.00 to $73.00 and set a “market outperform” rating for the company in a research report on Thursday, August 7th. William Blair reiterated a “market perform” rating on shares of Lantheus in a research report on Wednesday, July 16th. TD Cowen dropped their price objective on Lantheus from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Monday. Mizuho lowered their price target on Lantheus from $120.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, August 7th. Finally, Truist Financial set a $63.00 price target on Lantheus and gave the company a “hold” rating in a report on Monday, August 11th. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Lantheus currently has a consensus rating of “Moderate Buy” and an average price target of $85.50.

Lantheus Trading Up 0.5%

Lantheus stock opened at $51.98 on Tuesday. The stock has a market cap of $3.53 billion, a PE ratio of 13.82 and a beta of 0.15. The stock has a 50-day moving average price of $62.83 and a 200 day moving average price of $80.71. Lantheus has a 52 week low of $47.25 and a 52 week high of $118.21. The company has a current ratio of 4.29, a quick ratio of 4.07 and a debt-to-equity ratio of 0.49.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Wednesday, August 6th. The medical equipment provider reported $1.57 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.08). The company had revenue of $378.05 million for the quarter, compared to analysts’ expectations of $389.69 million. Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The company’s revenue for the quarter was down 4.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.80 EPS. Equities research analysts predict that Lantheus will post 6.01 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Lantheus news, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the transaction, the insider directly owned 3,477,227 shares of the company’s stock, valued at $195,246,296.05. This represents a 49.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Rajiv A. Patel sold 3,365,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the transaction, the insider directly owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. The trade was a 49.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 6,812,000 shares of company stock worth $382,427,380. 2.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Lantheus

A number of institutional investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Lantheus by 4.1% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 39,212 shares of the medical equipment provider’s stock valued at $3,508,000 after acquiring an additional 1,531 shares in the last quarter. ProShare Advisors LLC raised its position in shares of Lantheus by 41.2% during the 4th quarter. ProShare Advisors LLC now owns 22,646 shares of the medical equipment provider’s stock valued at $2,026,000 after acquiring an additional 6,606 shares in the last quarter. State of Wyoming raised its position in shares of Lantheus by 662.2% during the 4th quarter. State of Wyoming now owns 4,558 shares of the medical equipment provider’s stock valued at $408,000 after acquiring an additional 3,960 shares in the last quarter. Woodline Partners LP raised its position in shares of Lantheus by 2.7% during the 4th quarter. Woodline Partners LP now owns 88,018 shares of the medical equipment provider’s stock valued at $7,874,000 after acquiring an additional 2,340 shares in the last quarter. Finally, Peak Retirement Planning Inc. acquired a new stake in shares of Lantheus during the 4th quarter valued at approximately $917,000. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.